C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
C4 Therapeutics, Inc.NASDAQ: CCCC
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $24.61M fell 9.1% year over year, ahead of the -11.6% change in trailing-twelve-month research & development. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.
Context
- Research & development amounted to 290.0% of revenue in FY2025, down 20.9 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -9.1% holds above the trailing-twelve-month pace of -11.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 104.24M USD
- Year-over-year change
- -5.8%
- 4-year CAGR
- +2.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.24M | -5.8% |
| FY2024 | 2024-12-31 | 110.64M | -6.0% |
| FY2023 | 2023-12-31 | 117.71M | -0.1% |
| FY2022 | 2022-12-31 | 117.84M | +24.5% |
| FY2021 | 2021-12-31 | 94.67M | — |
Research & Development vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -11.6% is the 6th highest of 9, against a peer median of -1.1%.
- Research & development amounts to 291.9% of revenue for CCCC, versus a peer median of 576.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $113.23M USD | +11.4% | -23.3% | 327.7% | |
| LTM Mar 2026 | $101.77M USD | -11.6% | -4.0% | 291.9% | |
| LTM Mar 2026 | $58.35M USD | -32.7% | +9.5% | — | |
| LTM Mar 2026 | $47.7M USD | -0.5% | -13.2% | 61.1% | |
| LTM Mar 2026 | CHF 46.97M CHF | -1.7% | -7.5% | — | |
| LTM Mar 2026 | $44.75M USD | -15.8% | -0.4% | 154.8% | |
| LTM Mar 2026 | $24.4M USD | -23.4% | -12.2% | 824.8% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $17.59M USD | +68.3% | +29.6% | 902.4% |
| LTM Mar 2026 | $16.56M USD | +5.5% | -23.1% | 928.4% | |
| Peer median (excluding CCCC) | — | -1.1% | -9.8% | 576.3% | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.79M | 31.1M | 20.76M | 35.58M | 35.95M |
| Cost of Revenue | 0 | 0 | 7.74M | 0 | 7.98M |
| Gross Profit | 45.79M | 31.1M | 13.02M | 35.58M | 27.97M |
| Gross Margin | 100.0% | 100.0% | 62.7% | 100.0% | 77.8% |
| Research & Development | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
| Selling, General & Admin | 33.25M | 42.79M | 42.08M | 42.12M | 36.2M |
| Operating Expenses | 127.92M | 160.63M | 152.05M | 155.2M | 132.46M |
| Depreciation & Amortization | 1.49M | 1.68M | 7.74M | 1.82M | 1.96M |
| EBITDA | (80.26M) | (124.28M) | (122.1M) | (103.37M) | (102.91M) |
| EBITDA Margin | -175.3% | -399.7% | -588.3% | -290.5% | -286.3% |
| Operating Income | (82.13M) | (129.53M) | (139.03M) | (119.61M) | (104.49M) |
| Operating Margin | -179.4% | -416.6% | -669.8% | -336.1% | -290.7% |
| Interest Income | 387K | 3.58M | 9.81M | 14.43M | 10.35M |
| Interest Expense | 2.15M | 2.22M | 1.37M | 0 | 0 |
| Other Income / Expenses | (1.76M) | 1.36M | 7.82M | 14.43M | (384K) |
| Income Before Tax | (83.89M) | (128.18M) | (131.21M) | (105.19M) | (104.87M) |
| Pre-Tax Margin | -183.2% | -412.2% | -632.2% | -295.6% | -291.7% |
| Income Tax Expense | 0 | 0 | 1.28M | 131K | 121K |
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Net Margin | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| EPS (Basic) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| EPS (Diluted) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| Weighted Avg Shares | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
| Weighted Avg Shares (Diluted) | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.